UnitedHealth Group (NYSE:UNH) Director Rodger Lawson bought 1,000 shares of the stock in a transaction that occurred on Thursday, April 24th. The stock was purchased at an average price of $76.21 per share, with a total value of $76,210.00. Following the transaction, the director now directly owns 21,877 shares in the company, valued at approximately $1,667,246. UnitedHealth Group Inc. (NYSE:UNH) shares after opening at $75.95 moved to $76.21 on last trade day and at the end of the day closed at $75.20. Company price to sales ratio in past twelve months was calculated as 0.60 and price to cash ratio as 7.89. UnitedHealth Group Inc. (NYSE:UNH) showed a negative weekly performance of -0.74%.
Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost purchased 36,200 shares of Opko Health stock on the open market in a transaction dated Friday, April 25th. The stock was purchased at an average cost of $8.04 per share, for a total transaction of $291,048.00. Following the purchase, the chief executive officer now directly owns 1,987,500 shares in the company, valued at approximately $15,979,500. Opko Health Inc. (NYSE:OPK) shares advanced 2.85% in last trading session and ended the day on $8.31. OPK return on equity ratio is recorded as -19.30% and its return on assets is -11.30%. Opko Health Inc. (NYSE:OPK) yearly performance is 21.14%.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) Director Charles O’keeffe purchased 5,000 shares of the stock on the open market in a transaction that occurred on Wednesday, April 16th. The stock was purchased at an average cost of $2.02 per share, with a total value of $10,100.00. Following the acquisition, the director now directly owns 182,126 shares of the company’s stock, valued at approximately $367,895. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) shares moved up 0.50% in last trading session and was closed at $2.01, while trading in range of $1.97 – $2.05. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) year to date (YTD) performance is 3.08%.
OHR Pharmaceutical (NASDAQ:OHRP) Director June Sherie Almenoff acquired 5,500 shares of OHR Pharmaceutical stock in a transaction dated Tuesday, April 8th. The stock was purchased at an average cost of $10.25 per share, for a total transaction of $56,375.00. Following the purchase, the director now directly owns 122,166 shares of the company’s stock, valued at approximately $1,252,202. OHR Pharmaceutical Inc. (NASDAQ:OHRP) weekly performance is -1.12%. On last trading day company shares ended up $9.68. OHR Pharmaceutical Inc. (NASDAQ:OHRP) distance from 50-day simple moving average (SMA50) is -30.70%. Analysts mean target price for the company is $21.00.
Leave a Reply